Bicarbonate therapy for prevention of chronic kidney disease progression

Kidney International

Volumn 85, Issue 3, 2014, Pages 529-535

  Łoniewski, Igor ^a   Wesson, Donald E ^b,c  

^a Sanum Polska Sp Z Oo Ul Kurza Stopka   (Poland)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

alkali therapy; bicarbonate; chronic kidney disease

Indexed keywords

BICARBONATE; AMMONIUM CHLORIDE; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; CALCIUM CARBONATE; CALCIUM SALT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CITRATE CALCIUM; CITRATE POTASSIUM; CITRATE SODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPHEDRINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LITHIUM SALT; MEXILETINE; NORFLOXACIN; OFLOXACIN; PLACEBO; POTASSIUM DIHYDROGEN PHOSPHATE; QUINIDINE; SALICYLIC ACID DERIVATIVE; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; SUCRALFATE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

CHRONIC KIDNEY DISEASE; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ERUCTATION; FLATULENCE; HUMAN; HYPERNATREMIA; METABOLIC ALKALOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH DISTENSION; STOMACH RUPTURE; TREATMENT OUTCOME; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; ALKALINIZATION; BICARBONATE BLOOD LEVEL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COMPETITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; HYPERTENSION; HYPOKALEMIA; METABOLIC ACIDOSIS; MILK ALKALI SYNDROME; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PATIENT COMPLIANCE; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT;

DISEASE PROGRESSION; HUMANS; RENAL INSUFFICIENCY, CHRONIC; SODIUM BICARBONATE;

EID: 84895079730     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.401     Document Type: Short Survey

References (29)

1. Kovesdy CP. Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? Nephrol Dial Transplant 2012; 27: 3056-3062
2. Phisitkul S, Hacker C, Simoni J et al. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int 2008; 73: 192-199
3. Phisitkul S, Khanna A, Simoni J et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010; 7: 617-623
4. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009; 24: 1232-1237
5. Navaneethan SD, Schold JD, Arrigain S et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2395-2402
6. Kanda E, Ai M, Yoshida M et al. High serum bicarbonate level within the normal range prevents the progression of chronic kidney disease in elderly CKD patients. BMC Nephrol 2013; 14: 4
7. Dobre M, Yang W, Chen J et al. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2013; 62: 670-678
8. Scialla JJ, Appel LJ, Astor BC et al. African American Study of Kidney Disease and Hypertension Study Group. Net endogenous acid production is associated with a faster decline in GFR in African Americans. Kidney Int 2012; 82: 106-112
9. Wesson DE, Simoni J, Broglio K et al. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 2011; 300: F830-F837
10. Wesson DE, Simoni J. Increased tissue acid mediates progressive GFR decline in animals with reduced nephron mass. Kidney Int 2009; 75: 929-935
11. Wesson DE, Jo CH, Simoni J. Angiotensin II receptors mediate increased distal nephron acidification caused by acid retention. Kidney Int 2012; 82: 1184-1194
12. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulointerstitial disease in rats: interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76: 667-675
13. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084
14. Mahajan A, Simoni J, Sheather SJ et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010; 78: 303-309
15. Goraya N, Simoni J, Jo C et al. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 2012; 81: 86-93
16. Abramowitz MK, Melamed ML, Bauer C et al. Effects of oral sodium bicarboante in patients with CKD. Clin J Am Soc Nephrol 2013; 8: 714-720
17. Goraya N, Simoni J, Jo CH et al. Comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol 2013; 8: 371-381
18. Susantitaphong P, Sewaralthahab K, Balk EM et al. Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol 2012; 35: 540-547
19. Sun X, Yang LV, Tiegs BC et al. Deletion of the pH sensor GPR4 decreases renal acid excretion. J Amer Soc Nephrol 2012; 21: 1745-1755
20. Madias NE, Levey AS. Metabolic alkalosis due to absorption of "nonabsorbable" antacids. Am J Med 1983; 74: 155-158
21. Lin SH, Lin YF, Cheema-Dhadli S et al. Hypercalcaemia and metabolic alkalosis with betel nut chewing:emphasis on its integrative patophysiology. Nephrol Dial Tranplant 2002; 17: 708-7147
22. Rutkowski B, Ciechanowski K. Rola alkalizacji w nefroprotekcji-nowe spojrzenie na stary problem. The role of alkalization in nephroprotection-new look on the old problem. Forum Nefrol 2012; 5: 265-271
23. Gammelin G, Resch KL. Incidence of stomach ruptures after ingestion of sodium bicarbonate-containing or carbonated beverages. Forsch Komplementarmed Klass Naturheilkd 2000; 7: 228-232
24. Husted FC, Nolph KD. NaHCO 3 and NaCl tolerance in chronic renal failure. II. Clin Nephrol 1977; 7: 21-25
25. Kovesdy CP, Lott EH, Lu JL et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012; 125: 677-684
26. Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011; 26: 19-28
27. Adrogue HJ, Brensilver J, Cohen JJ et al. Influence of steady-state alterations in acid-base equilibrium on the fate of administered bicarbonate in the dog. J Clin Invest 1983; 71: 687-883
28. Krapf R, Seldin DW, Alpern RJ. Clinical syndromes of metabolic acidosis. In Alpern RJ, Hebert SC (eds). Seldin and Giebischs The Kidney: Physiology and Patophysiology vol 2 (Academic Press is an imprint of Elsevier: Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokio), 2008, pp 1704
29. Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis 2012; 19: 11-18.